Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=150 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
Hepatitis B, Chronic
Primary: Percentage of Participants With Hepatitis B Virus DNA <100,000 Copies/mL At Week 72 — 20.9; 21.9 percentage of participants
Phase 2 N=4 Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy
Urticaria
Primary: Number of Participants With Adverse Events — 3 participants
Phase 4 N=12 An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine
Acne Scars
Primary: Evaluation of Acne Scarring and the Surrounding Skin Using the Global Aesthetic Improvement Scale — 100 percentage of participants
Phase 3 N=239 Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis
Target Bleeding Site During Peripheral Vascular Surgery
Primary: The Primary Efficacy Endpoint is Time to Hemostasis. — 46.4; 26.3; 62.7; 31.6 percentage of subjects
N/A N=23 Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)
Secondary Hyperparathyroidism
Primary: Number of Participants With iPTH Levels Maintained at the Target Levels of 60-180 pg/mL iPTH Level — 10; 4; 2; 7 participants — p=0.036
Phase 4 N=643 Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
Post Menopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 - Non-inferiority Analysis — 1.1; 3.2 percent change — p=<0.0001
Phase 2 N=78 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Bladder Cancer · Transitional Cell Cancer of the Renal Pelvis and Ureter · Urethral Cancer
Primary: Overall Objective Response — 3; 29; 39 participants
Phase 2 N=124 Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Adenocarcinoma of the Stomach · Recurrent Gastric Cancer
Primary: Median Progression-free Survival (PFS) — 8.77; 8.35 months — p=0.874
N/A N=15 Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources
Parkinson's Disease
Primary: Median Time Used by Investigator, Duodopa Nurse Specialist, Telemedicine (TM) Technician, and Participant — 29.1; 22.2; 30.0; NA Minutes
Phase 2 N=61 Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.
Esophageal Carcinoma
Primary: Pathologic Complete Response — 55 participants
Phase 2 N=47 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Sarcoma · Leiomyosarcoma · Malignant Fibrous
Primary: Overall Objective Response — 0; 1; 9; 1 participants
Phase 2 N=118 Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Lymphoma
Primary: Objective Response — 3; 6; 3; 2 participants
Phase 2 N=50 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
CNS Cancer · Meningioma · Intracranial Hemangiopericytoma
Primary: Overall Objective Response — 1; 0; 1; 0 participants
Phase 3 N=319 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
Cancer
Primary: Neurotoxicity Assessment at Baseline — 8.5; 7.3; 5.23; 4.58 units on a scale